Quinolones (ATC-group J01M): the state of the pharmaceutical market, analysis of consumption in Ukraine and in some European countries in 2013-2018
DOI:
https://doi.org/10.24959/cphj.20.1519Keywords:
quinolones, fluoroquinolones, antibacterial drugs, consumption, antibiotic resistanceAbstract
The synthesis of the first antibiotic of the Quinolone group took place in 1958. Since then, Quinolones are widely used in clinical practice around the world due to their wide antibacterial spectrum of action.
Aim. To study the pharmaceutical market of Ukraine of the Quinolone antibiotics group, as well as determine the volumes of their consumption in 2013-2018.
Materials and methods. The analysis of the assortment of antibiotics of the Quinolone group was carried out according to the WHO Collaborating Center by methodologies for statistical analysis of drugs and according to the State Register of Medicines of Ukraine. The consumption was calculated using a standardized ATC/DDD methodology recommended by the WHO.
Results. Eleven INNs of the Quinolone group antibiotics are presented at the pharmaceutical market of Ukraine, as well as 6 INNs of combinations with Quinolones. In 2018, 159 trade names (TNs) of Quinolones were registered in Ukraine; 40.25 % of them are of domestic production (64 TNs). The consumption of Quinolones for the study period increased from 1.77 DID in 2016 to 1.83 DID in 2018. In general, the ABD consumption in the countries of the European Union and the European Economic Area (EU/EEA) decreased during the study period from с 1.77 DID in 2013 to 1.5 DID in 2018.
Conclusions. Eleven INNs of Quinolone group antibiotics are presented at the pharmaceutical market of Ukraine, as well as 6 INNs of combinations with Quinolones presented by 159 TNs in 2018. The consumption of Quinolones increased over the study period from 1.77 DID in 2016 to 1.83 DID in 2018. Within 2013-2016 the consumption of Quinolone antibiotics in Ukraine was lower than in the EU/EEA, but in 2017 the consumption in Ukraine increased to 0.15 DID, and in 2018 the difference increased to 0.33 DID.References
Lack of new antibiotics threatens global efforts to contain drug-resistant infections. (2020). WHO News release. 17 January 2020. Geneva. Available at: https://www.who.int/news-room/detail/17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections (date of access: 20.01.2020).
Carroll, G. (1963). Neggram (nalidixic Acid): A New Antimicrobial Chemotherapeutic Agent. Journal of Urology, 90(4), 476–480. https://doi.org/10.1016/s0022-5347(17)64441-0
Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H., & Brundage, R. P. (1962). 1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents. Journal of Medicinal and Pharmaceutical Chemistry, 5(5), 1063–1065. https://doi.org/10.1021/jm01240a021
Autio, S., Makela, P., & Sunila, R. (1966). Experience with Nalidixic Acid in the Treatment of Urinary Tract Infections of Children. Archives of Disease in Childhood, 41(218), 395–399. https://doi.org/10.1136/adc.41.218.395
Barton, N., Crowther, A. F., Hepworth, W., Richardson, N. D., Driver, G. W. (1960). New Quinolones and Therapeutic Compositions Containing Them. GB830832.
Pham, T., Ziora, Z. M., & Blaskovich, M. (2019). Quinolone antibiotics. MedChemComm, 10(10), 1719–1739. https://doi.org/10.1039/c9md00120d
King, D. E., Malone, R., & Lilley, S. H. (2000). New classification and update on the quinolone antibiotics. American family physician, 61(9), 2741–2748.
WHO Collaborating Centre for Drug Statistics Methodology. (n.d.). Available at: https://www.whocc.no/atc_ddd_index/ (date of access: 21.01.2020).
Naber, K. G., & Adam, D. (1998). Classification of fluoroquinolones. International Journal of Antimicrobial Agents, 10(4), 255–257. https://doi.org/10.1016/s0924-8579(98)00059-4
Makino, M. (1968). Hinyokika kiyo. Acta urologica Japonica, 14(6), 351–356.
Sharma, P. C., Jain, A., & Jain, S. (2009). Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta poloniae pharmaceutica, 66(6), 587–604.
Pham, T., Ziora, Z. M., & Blaskovich, M. (2019). Quinolone antibiotics. MedChemComm, 10(10), 1719–1739. https://doi.org/10.1039/c9md00120d
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. (n.d.). Departament farmatsevtychnoi diialnosti, Derzhavnyi ekspertnyi tsentr Ministerstva okhorony zdorovia Ukrainy. Available at: http://www.drlz.com.ua (data zvernennia: 20.01.2020).
Systema doslidzhennia rynku likarskykh zasobiv «Farmstandart» kompanii «Morion». (n.d.). Available at: http://www.pharmstandart.com.ua (data zvernennia: 20.01.2020).
Morozov, A. M., Yakovlieva, L. V., Stepanenko, A. V., Zimenkovskyi, A. B., Parii, V. D., Dumenko, T. M., Matiashova, N. O., Adonkina, V. Yu. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATC/DDD-metodolohiia): Metod. Rekomendatsii. Kyiv: NFaU, DETs MOZ Ukrainy, 32.
European Surveillance of Antimicrobial Consumption Network. Publications & data. Reports for (2015, 2016, 2017, 2018). Available at: https://www.ecdc.europa.eu/en/publications-data (date of access:01.02.2020).
Psaty, B. M. (2008). Clinical Trial Design and Selected Drug Safety Issues for Antibiotics Used to Treat Community‐Acquired Pneumonia. Clinical Infectious Diseases, 47(S3), S176–S179. https://doi.org/10.1086/591400
Owens, R. C., & Ambrose, P. G. (2000). Clinical use of the fluoroquinolones. Medical Clinics of North America, 84(6), 1447–1469. https://doi.org/10.1016/S0025-7125(05)70297-2
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
